Crinetics Pharmaceuticals, Inc. (CRNX)
Last updated: 2026-10-20 10:28:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
Crinetics Pharmaceuticals, Inc. (CRNX) Pre-Market Stock Price
Crinetics Pharmaceuticals, Inc. (CRNX) is trading at $-- in pre-market trading as of --, -- from the previous close of $--
Pre-market trading shows how investors are pricing CRNX before the regular session opens. The current pre-market price is -- the previous close, indicating -- early trading sentiment.
Crinetics Pharmaceuticals, Inc. (CRNX) 7-Day Stock Price Change
Over the past seven days, Crinetics Pharmaceuticals, Inc. (CRNX) moved from $84.70 to $84.95, representing a gain of 0.30% ($0.25).
The stock traded between $84.69 and $85.01 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 2.15 million shares, down versus the previous seven-day period, indicating lower trading activity.
What is Crinetics Pharmaceuticals, Inc. (CRNX)?
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Crinetics Pharmaceuticals, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 594 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Crinetics Pharmaceuticals, Inc. (CRNX) Stock on MEXC
Eligible investors can buy real shares of Crinetics Pharmaceuticals, Inc. (CRNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Crinetics Pharmaceuticals, Inc. (CRNX) stock price today?
2.Is CRNX stock going up or down today?
3.What is CRNX pre-market price?
4.What is CRNX after-hours price?
5.Is CRNX stock trading now?
6.Where does CRNX sit relative to its 52-week high and low?
7.What sector is Crinetics Pharmaceuticals, Inc. in?
8.What is Crinetics Pharmaceuticals, Inc.'s market capitalization and where is it listed?
9.How is CRNX valued in terms of P/E ratio and EPS?
10.Does Crinetics Pharmaceuticals, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CRNX Stock Calculator
Estimate the value between CRNX shares and USD.
CRNX Shares to USD
1.00 CRNX shares = 0 USD
Calculations are estimates based on the latest available price and are for reference only.


